<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Inst Med Trop Sao Paulo</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev. Inst. Med. Trop. Sao Paulo</journal-id>
      <journal-title-group>
        <journal-title>Revista do Instituto de Medicina Tropical de S&#xE3;o Paulo</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-4665</issn>
      <issn pub-type="epub">1678-9946</issn>
      <publisher>
        <publisher-name>Instituto de Medicina Tropical</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24213197</article-id>
      <article-id pub-id-type="pmc">4105092</article-id>
      <article-id pub-id-type="publisher-id">S0036-46652013000600010</article-id>
      <article-id pub-id-type="doi">10.1590/S0036-46652013000600010</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>CASE STUDY OF A PATIENT WITH HIV-AIDS AND VISCERAL
LEISHMANIASIS CO-INFECTION IN MULTIPLE EPISODES</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Estudo de caso de paciente com m&#xFA;ltiplos epis&#xF3;dios da coinfec&#xE7;&#xE3;o
HIV-AIDS e leishmaniose visceral</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva</surname>
            <given-names>Elis Dion&#xED;sio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Andrade</surname>
            <given-names>Luiz Dias</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Ara&#xFA;jo</surname>
            <given-names>Paulo S&#xE9;rgio Ramos</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silveira</surname>
            <given-names>Vera Magalh&#xE3;es</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Padilha</surname>
            <given-names>Carlos Eduardo</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva</surname>
            <given-names>Maria Almerice Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Medeiros</surname>
            <given-names>Zulma Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
        <aff id="aff1"><label>1</label> Postgraduate Course of Biology applied to Health, Federal University
of Pernambuco, PE, Brazil. E-mail: <email>dionisio.elis@gmail.com</email><email>dionisio.elis@gmail.com</email></aff>
        <aff id="aff2"><label>2</label> Graduate Course on Biological Sciences, Institute of Biological
Sciences, University of Pernambuco, PE, Brazil</aff>
        <aff id="aff3"><label>3</label> Parasitology Department, Aggeu Magalh&#xE3;es Research Center, Oswaldo
Cruz Foundation, PE, Brazil. E-mails: <email>dias@cpqam.fiocruz.br</email><email>almerice@cpqam.fiocruz.br</email><email>dias@cpqam.fiocruz.br</email><email>almerice@cpqam.fiocruz.br</email></aff>
        <aff id="aff4"><label>4</label> Tropical Medicine Department, Clinical Hospital, Federal University
of Pernambuco, PE, Brazil. E-mails: <email>psergio@cpqam.fiocruz.br</email><email>vemagalhaes@uol.com.br</email><email>psergio@cpqam.fiocruz.br</email><email>vemagalhaes@uol.com.br</email></aff>
        <aff id="aff5"><label>5</label> Service of Infectious and Parasitic Diseases, Clinical Hospital,
Federal University of Pernambuco, Brazil. E-mail: <email>cegpadilha@gmail.com</email><email>cegpadilha@gmail.com</email></aff>
        <aff id="aff6"><label>6</label> Pathology Department, Institute of Biological Sciences, University
of Pernambuco, PE, Brazil. E-mail: <email>medeiros@cpqam.fiocruz.br</email><email>medeiros@cpqam.fiocruz.br</email></aff>
      </contrib-group>
      <author-notes>
        <corresp><bold>Correspondence to:</bold> Zulma M. Medeiros, Centro de Pesquisas Aggeu
Magalh&#xE3;es CPqAM/Fiocruz, Av. Professor Moraes Rego s/n, 50670-420 Cidade
Universit&#xE1;ria, Recife, PE, Brazil. E-mail: <email>medeiros@cpqam.fiocruz.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>55</volume>
      <issue>6</issue>
      <fpage>425</fpage>
      <lpage>428</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>11</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>SUMMARY</title>
          <p id="para1">Report of a 45-year-old male farmer, a resident in the forest zone of
Pernambuco, who was diagnosed with human immunodeficiency virus (HIV) in 1999 and
treated using antiretroviral (ARV) drugs. In 2005, the first episode of visceral
leishmaniasis (VL), as assessed by parasitological diagnosis of bone marrow
aspirate, was recorded. When admitted to the hospital, the patient presented
fever, hepatosplenomegaly, weight loss, and diarrhea. Since then, six additional
episodes of VL occurred, with a frequency rate of one per year (2005-2012, except
in 2008). In 2011, the patient presented a disseminated skin lesion caused by the
amastigotes of <italic>Leishmania</italic>, as identified by histopathological
assessment of skin biopsy samples. In 2005, he was treated with
N-methyl-glucamine-antimony and amphotericin B deoxycholate. However, since 2006
because of a reported toxicity, the drug of choice was liposomal amphotericin B.
As recommended by the Ministry of Health, this report emphasizes the need for HIV
patients living in VL endemic areas to include this parasitosis in their follow-up
protocol, particularly after the first infection of VL.</p>
        </sec>
      </abstract>
      <trans-abstract xml:lang="pt">
        <sec>
          <title>RESUMO</title>
          <p id="para2">Relato de caso de paciente masculino de 45 anos, agricultor, residente
na zona da mata do Estado de Pernambuco, diagnosticado com HIV em 1999 e em uso de
ARV. Em 2005 foi registrada a primeira ocorr&#xEA;ncia de LV atrav&#xE9;s do diagn&#xF3;stico
parasitol&#xF3;gico a partir do aspirado da medula &#xF3;ssea. &#xC0; admiss&#xE3;o no hospital
apresentava-se com febre, hepatoesplenomegalia, perda de peso e diarr&#xE9;ia. Desde
ent&#xE3;o houve a ocorr&#xEA;ncia de mais sete epis&#xF3;dios de LV, tendo ocorrido em media, um
evento a cada ano (2005-2012 exceto em 2008). O paciente apresentou, em 2011, um
quadro cut&#xE2;neo disseminado, sendo realizada biopsia de pele que evidenciou formas
amastigotas de <italic>Leishmania</italic> no exame histopatol&#xF3;gico. Em 2005, o
tratamento foi realizado com antimoniato de N-metil-glucamina e anfotericina B
desoxicolato, mas desde 2006, devido &#xE0; toxicidade, o medicamento de escolha foi a
anfotericina B lipossomal. Como recomendado pelo Minist&#xE9;rio da Sa&#xFA;de, esse relato
refor&#xE7;a a necessidade de que os casos de HIV residentes em &#xE1;rea end&#xEA;mica de LV
dever&#xE3;o ter inserido em seu protocolo de acompanhamento essa parasitose,
principalmente ap&#xF3;s o primeiro epis&#xF3;dio.</p>
        </sec>
      </trans-abstract>
      <kwd-group>
        <kwd>Co-infection</kwd>
        <kwd>Visceral leishmaniasis</kwd>
        <kwd>HIV infection</kwd>
        <kwd>AIDS</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="1"/>
        <ref-count count="28"/>
        <page-count count="4"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p id="para3">Cases of visceral leishmaniasis (VL) co-infection with human immunodeficiency
virus (HIV) and acquired immune deficiency syndrome AIDS (VL/HIV-AIDS) have been
registered in 35 countries, mainly in southwestern Europe. VL/HIV-AIDS co-infections
increase in areas where these two diseases coexist, as observed in Asian, African, and
Latin American countries. In the latter group, Brazil has the highest number of
cases<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref> .</p>
      <p id="para4">In 2011, in Brazil, VL appeared in 22 of the 27 Brazilian states, covering
urban and suburban areas. Between 1998 and 2009, the annual average was 3,349 cases<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>. From 1980 to 2011 in Brazil, 608,230 cases of AIDS were reported. This epidemic
tends to spread to poorly inhabited macro-regions as well as to medium and small
cities<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>. When AIDS and VL databases were correlated, 176 cases of VL/HIV-AIDS
co-infection were detected among the Federal States<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>.</p>
      <p id="para5">Several episodes of VL are frequent in cases of VL/HIV-AIDS co-infection.
According to BOURGEOIS <italic>et al.</italic>, 2010, these patients present a novel
nosological entity called &#x2018;active chronic visceral leishmaniasis&#x2019;. This condition may be
termed &#x2018;chronic&#x2019; because of the presence of relapses over a period of several years and
&#x2018;active&#x2019; because of the continuous blood circulation of the parasite. On the other hand,
it's impossible to know if repeated episodes are relapses or reinfections by using
conventional parasitological and immunological methods<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>. Some studies show that individuals with HIV/AIDS and infected with VL often
present atypical clinical manifestations and high incidence of relapse<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>
<xref rid="B24" ref-type="bibr">
<sup>24</sup>
</xref>
<xref rid="B25" ref-type="bibr">
<sup>25</sup>
</xref>. Molecular methods confirm that more than 90% of these cases are relapses,
rather than reinfections<xref rid="B27" ref-type="bibr">
<sup>27</sup>
</xref>. The discrimination between relapses and reinfection can be made by molecular
techniques based on restriction fragment length polymorphism (RFLP) analysis. The use of
this technology may provide the physician with more information to determine
<italic>Leishmania</italic> infections in patients who do not respond to
treatment<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>.</p>
      <p id="para6">Professionals, who treat patients with HIV/AIDS, report that this
co-infection was not prioritized because of the variety of diseases related to
immunosuppression, in addition to not being included among the AIDS-defining
conditions<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. To alert healthcare professionals about this association, we describe the case
of a patient presenting multiple VL/HIV-AIDS co-infections during the seven years of
evolution of this disease.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p id="para7">In 1999, a 31-year-old male farmer, who was a resident in the forest zone of
Pernambuco, was admitted to the Clinics Hospital of the Federal University of
Pernambuco. At the time of admission, he presented with asthenia and headache, and had
diarrhea for at least 30 days. He was diagnosed with HIV, and began receiving
antiretroviral therapy (ART) with stavudine, lamivudine, and efavirenz. Meanwhile, his
25-year-old partner and 9-month-old daughter were diagnosed with HIV infection.</p>
      <p id="para8">Five years after initiating ART, the patient presented virological failure;
after genotyping, his treatment was changed to tenofovir, lamivudine, and
lopinavir/ritonavir. In 2005, he was diagnosed with VL as assessed by directly testing
<italic>Leishmania</italic> in the bone marrow aspirate and initially treated with
N-methyl-glucamine-antimony. However, because of pancreatitis, the patient began
receiving amphotericin B, which was then replaced by a liposomal formulation because of
the onset of renal failure.</p>
      <p id="para9">In 2011, the patient presented disseminated cutaneous lesions caused by
<italic>Leishmania</italic>, as assessed by histopathological analysis of skin biopsy
samples. In July 2012, the patient was readmitted for presenting febrile disease with
splenomegaly and pancytopenia, in addition to showing positive results for laboratory
tests for leishmaniasis (<xref ref-type="table" rid="t01">Table 1</xref>). After
administration of liposomal amphotericin B deoxycholate, the patient's condition
improved, and he was discharged upon recommendation of a secondary prophylaxis by
administering liposomal amphotericin B twice a week. Between 2005 and 2012, seven VL
infections occurred, as shown in the <xref ref-type="table" rid="t01">Table
1</xref>.</p>
      <p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>Description of clinical events, additional diagnostics, and treatment for
the case of co-infection from Pernambuco, between 1999 and 2012</title></caption><table frame="hsides" rules="groups" width="95%"><thead style="border-bottom: thin solid; border-top: thin solid; border-color: #000000"><tr><th align="left" rowspan="1" colspan="1">Period (month/year)</th><th rowspan="1" colspan="1">Clinical events</th><th rowspan="1" colspan="1">CD4+ T cells (cells/mm<sup>3</sup>)</th><th rowspan="1" colspan="1">Viral load (copies/mL)</th><th rowspan="1" colspan="1">Laboratory diagnosis</th><th rowspan="1" colspan="1">Treatment</th><th rowspan="1" colspan="1">Prophylactic treatment</th></tr></thead><tbody style="border-color: #000000; border-bottom: thin solid"><tr><td align="left" rowspan="1" colspan="1">09/99</td><td align="center" rowspan="1" colspan="1">Positive for HIV</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">d4T + 3TC + EFV</td><td align="center" rowspan="1" colspan="1">N.A.</td></tr><tr><td align="left" rowspan="1" colspan="1">05/04</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">208,000</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr</td><td align="center" rowspan="1" colspan="1">N.A.</td></tr><tr><td align="left" rowspan="1" colspan="1">03/05</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">29,000</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr</td><td align="center" rowspan="1" colspan="1">N.A.</td></tr><tr><td align="left" rowspan="1" colspan="1">06/05</td><td align="center" rowspan="1" colspan="1">Visceral leishmaniasis
(Hepatosplenomegaly/diarrhea/fever/ cachexia/pancytopenia)</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">B.M. aspirate</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr
N-methyl-glucamine-antimony<xref ref-type="table-fn" rid="TFN02t01">a</xref>, amphotericin B<xref ref-type="table-fn" rid="TFN03t01">b</xref>, liposomal amphotericin</td><td align="center" rowspan="1" colspan="1">N.A.</td></tr><tr><td align="left" rowspan="1" colspan="1">11/05</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">87,800</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr</td><td align="center" rowspan="1" colspan="1">N.A.</td></tr><tr><td align="left" rowspan="1" colspan="1">02/06</td><td align="center" rowspan="1" colspan="1">Visceral leishmaniasis (Second
infection)</td><td align="center" rowspan="1" colspan="1">170</td><td align="center" rowspan="1" colspan="1">&lt;50</td><td align="center" rowspan="1" colspan="1">B.M. aspirate</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr liposomal
amphotericin</td><td align="center" rowspan="1" colspan="1">N-methyl-glucamine-antimony</td></tr><tr><td align="left" rowspan="1" colspan="1">02/07</td><td align="center" rowspan="1" colspan="1">Visceral leishmaniasis (Third
infection)</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">B.M. aspirate</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr liposomal
amphotericin</td><td align="center" rowspan="1" colspan="1">N.D</td></tr><tr><td align="left" rowspan="1" colspan="1">06/08</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">113</td><td align="center" rowspan="1" colspan="1">&lt;50</td><td align="center" rowspan="1" colspan="1">N.A.</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr</td><td align="center" rowspan="1" colspan="1">Amphotericin B</td></tr><tr><td align="left" rowspan="1" colspan="1">07/09</td><td align="center" rowspan="1" colspan="1">Visceral leishmaniasis (Fourth
infection)</td><td align="center" rowspan="1" colspan="1">141</td><td align="center" rowspan="1" colspan="1">&lt;50</td><td align="center" rowspan="1" colspan="1">B.M. aspirate</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr liposomal
amphotericin</td><td align="center" rowspan="1" colspan="1">Amphotericin B</td></tr><tr><td align="left" rowspan="1" colspan="1">05/10</td><td align="center" rowspan="1" colspan="1">Visceral leishmaniasis (Fifth
infection)</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">&lt;50</td><td align="center" rowspan="1" colspan="1">B.M. aspirate</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr liposomal
amphotericin</td><td align="center" rowspan="1" colspan="1">Amphotericin B</td></tr><tr><td align="left" rowspan="1" colspan="1">05/11</td><td align="center" rowspan="1" colspan="1">Skin lesions on the
forehead/right forearm; Visceral leishmaniasis (Sixth infection)</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">&lt;50</td><td align="center" rowspan="1" colspan="1">Skin biopsy, rK39 rapid test,
DAT, latex agglutination test, and PCR</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr liposomal
amphotericin</td><td align="center" rowspan="1" colspan="1">Liposomal amphotericin</td></tr><tr><td align="left" rowspan="1" colspan="1">07/12</td><td align="center" rowspan="1" colspan="1">Visceral leishmaniasis (Seventh
infection) (Splenomegaly/diarrhea/fever/cachexia/pancytopenia)</td><td align="center" rowspan="1" colspan="1">114</td><td align="center" rowspan="1" colspan="1">&lt;50</td><td align="center" rowspan="1" colspan="1">rK39 rapid test , DAT, latex
agglutination test, and PCR</td><td align="center" rowspan="1" colspan="1">TDF + 3TC + LPVr amphotericin
B<xref ref-type="table-fn" rid="TFN03t01">b</xref>, liposomal
amphotericin</td><td align="center" rowspan="1" colspan="1">Liposomal amphotericin</td></tr></tbody></table><table-wrap-foot><fn id="TFN01t01"><p>HIV, human immunodeficiency virus; N.A., not available; N.D., not done; B.M.
aspirate, bone marrow aspirate; d4T, stavudine; 3TC, lamivudine; EFV,
efavirenz; TDF, tenofovir; LPVr, lopinavir/ritonavir; DAT, direct
agglutination test; PCR, polymerase chain reaction.</p></fn><fn id="TFN02t01"><label>a</label><p>Developed acute pancreatitis.</p></fn><fn id="TFN03t01"><label>b</label><p>Developed renal failure.</p></fn></table-wrap-foot></table-wrap>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p id="para10">This case describes some of the many clinical, diagnostic, and epidemiologic
aspects of VL/HIV-AIDS co-infection. Immunosuppression caused by HIV might lead to the
development of symptomatic VL<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>. In turn, VL might promote the clinical progression of HIV and of AIDS-defining
conditions, thus, reducing the possibility of recovery after treatment and increasing
the incidence of relapse<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. This report showed that individuals with HIV/AIDS and living in endemic areas
of VL should include VL assessment in their follow-up protocol. After the first
co-infection, by means of clinical and laboratory support, a follow-up protocol of the
patient should be created for early detection of relapse and re-infection.</p>
      <p id="para11">One of the common features of co-infection is the increased tendency of
relapse, observed in 37-80% of the patients<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>. Additionally, in some cases a chronic course with multiple occurrences might
take place. This can be attributed not only to immunodeficiency but also to
re-infection, host deficiencies correlating with ART, secondary prophylaxis, and CD4+
lymphocyte count<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>. CD4+ lymphocyte count is one of the most significant prognostic factors for
survival<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>. VL usually appears as an opportunistic disease in HIV patients when CD4+ cell
count is less than 200 cells/mm<sup>3(1,6,12,13,17,25)</sup>. During the seven years of
follow-up, the patient presented a CD4+ cell count &#x2264; 170 cells/mm<sup>3</sup>. This
represents an important predictor of relapse. Relapses of VL are suggested to occur
mainly in individuals with poor responses to antiretroviral treatment who have no
improvement in CD4+ counts with a few exceptions<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>.</p>
      <p id="para12">Based on clinical and biological [polymerase chain reaction (PCR)-based]
follow-up, an &#x2018;active chronic visceral leishmaniasis&#x2019;<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref> has been proposed by BOURGEOIS <italic>et al.</italic> (2010). In our case, only
the 6<sup>th</sup> and 7<sup>th</sup> episodes were able to have the peripheral blood
(PB) analyzed by PCR, which showed positive results for <italic>Leishmania</italic> spp.
As PCR-RFLP was only found in the 7<sup>th</sup> sample episode, the etiological agent
is <italic>Leishmania chagasi</italic>, according to the pattern of bands defined by
SCHONIAN <italic>et al.</italic> (2003)<xref rid="B26" ref-type="bibr">
<sup>26</sup>
</xref>. Due to the absence of PB samples in previous episodes, the analysis by PCR-RFLP
was not made. Therefore, it wasn't possible to distinguish between relapse and
reinfection or characterize the case as &#x2018;chronic visceral leishmaniasis&#x2019;. Despite the
medical importance of a clinical and laboratory monitoring of coinfected patients, this
practice is still little used<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>.</p>
      <p id="para13">ART plays an important role in reducing the effect of opportunistic diseases
and in recent studies has shown a reduction in the incidence of VL. Studies in
individuals with HIV/AIDS treated using ARV drugs showed a similar incidence of VL
relapse when compared to studies of the pre-highly active antiretroviral therapy (HAART)
era<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>. The increased survival resulting from ART might partially explain the high
incidence of relapse observed in this population<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>. In the present study, during the eight years of follow-up, we observed seven VL
infections, despite the patient receiving ART before the first infection.</p>
      <p id="para14">VL manifestations associated with HIV infection might appear in a classical
form, particularly in patients from VL-endemic areas, as well as with relatively
aggressive symptoms that are sometimes non-specific and difficult to clinically
diagnose<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. In individuals with HIV/AIDS and presenting symptoms such as asthenia,
anorexia, and weight loss, VL might be responsible for 7-23% of instances of fever of
unknown origin<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. This patient presented classic clinical manifestations during the study period,
although in 2011, we observed the formation of skin lesions because of the parasite, as
assessed by histopathological analysis.</p>
      <p id="para15">Among the previously treated VL cases, several patients present a skin
condition characterized by macular, popular, or nodular lesions, called Post-kala-azar
dermal Leishmaniasis (PKDL) caused by the amastigotes of <italic>Leishmania
donovani</italic> on the Indian subcontinent (India, Nepal, Bangladesh) and east
Africa (Sudan, Ethiopia, Kenya) and caused by <italic>Leishmania chagasi</italic> in
South America where it is rarely reported, as well as its presence in HIV positives<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<xref rid="B23" ref-type="bibr">
<sup>23</sup>
</xref>
<xref rid="B28" ref-type="bibr">
<sup>28</sup>
</xref>. It is worth noticing that exclusive involvement of the skin is an unusual
condition, because the simultaneous appearance of skin lesions along with other VL
manifestations was more frequently observed<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>. In this case, the skin lesion suggests a clinical PKDL, which developed five
years after the first VL episodes, administration of multiple therapeutic regimens, and
treatments of discontinuous secondary prophylaxis. Although it has been viewed
amastigotes in biopsy specimens obtained from skin lesions, the hypothesis of PKDL can
be suggested but not stated categorically because there was no characterization of
<italic>Leishmania</italic> species involved in the cutaneous lesions, and may have
been an infection of some sort cutaneous <italic>Leshmania</italic> endemic to the
region as <italic>L. braziliensis</italic>.</p>
      <p id="para16">Several studies on co-infected individuals show that they present a decrease
in anti-<italic>Leishmania</italic> antibody levels in the peripheral blood<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>; that is, in only 40-50% of VL/HIV-AIDS cases, specific antibodies are
detected<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref> . Conversely, assessment of <italic>Leishmania</italic> antigen in urine by
latex agglutination test showed a sensitivity of 85-100%<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref> . Polymerase chain reaction (PCR) in peripheral blood and bone marrow is a
useful tool to diagnose, for follow-up, and detect relapses<xref rid="B22" ref-type="bibr">
<sup>22</sup>
</xref>. Although the literature shows that serological analyses are not the most
convenient in patients presenting co-infection<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>, two serological tests (direct agglutination test and rK39-based rapid
immunochromatographic test) performed enabled the diagnosis of such cases in 2011 and
2012. In the same years, latex agglutination test and PCR test showed positive results,
thus, confirming the data in the literature. Similar to the finding in our study,
CAVALCANTI <italic>et al.</italic> (2012), described a series of case studies of
co-infection in the main hospitals of Recife, Brazil<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>.</p>
      <p id="para17">There is currently sufficient evidence suggesting that secondary prophylaxis
provides some protective effect but does not completely prevent the occurrence of
relapse<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>. A meta-analysis study described that the average incidence of relapse in
patients who did not receive secondary prophylaxis was 67%, whereas in those who
received it was 31%<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>. Current recommendations from the Ministry of Health of Brazil<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref> for the diagnosis, treatment, and follow-up of patients presenting co-infection
state that the &#x201C;efficacy of the secondary prophylaxis after the first successfully
treated VL infection, was not completely established.&#x201D; The suggested secondary
prophylaxis (<xref ref-type="table" rid="t01">Table 1</xref>) was poorly adopted, thus,
compromising the clinical follow-up. Based on this case study and literature review, it
is evident that co-infection presents typical clinical, diagnostic, and therapeutic
features, and can be observed in the prognosis of the disease. Therefore, prospective
studies are required to clarify gaps such as the efficacy of secondary prophylaxis and
need for clinical and laboratory monitoring tools for the early assessment of relapse or
re-infection.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p id="para18">This study was supported by the FACEPE/MS/CNPq Programme for Research and
priority development to unified health system - SUS/ PCT Sa&#xFA;de II (project 03/2004) and
CNPq/PIBIC/Fiocruz (process 139172/2012-2).</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alvar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ca&#xF1;avate</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Guti&#xE9;rrez-Solar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jim&#xE9;nez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Laguna</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez-V&#xE9;lez</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>
<italic>Leishmania</italic> and human immunodeficiency virus coinfection: the
first 10 years</article-title>
          <source>Clin Microbiol Rev</source>
          <year>1997</year>
          <volume>10</volume>
          <fpage>298</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="pmid">9105756</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Badar&#xF3;</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Queiroz</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>
<italic>Leishmania donovani</italic>: an opportunistic microbe associated with
progressive disease in three immunocompromised patients</article-title>
          <source>Lancet</source>
          <year>1986</year>
          <volume>1</volume>
          <issue>(8482)</issue>
          <fpage>647</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">2869348</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berenguer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cosin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Miralles</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Padilla</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Discontinuation of secondary
anti-<italic>Leishmania</italic> prophylaxis in HIV-infected patients who have
responded to highly active antiretroviral therapy</article-title>
          <source>AIDS</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>2946</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">11153679</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bittencourt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Straatmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nunes</surname>
              <given-names>VL</given-names>
            </name>
            <name>
              <surname>Follador</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Badar&#xF3;</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Post kala-azar dermal leishmaniasis associated with
AIDS</article-title>
          <source>Braz J Infect Dis</source>
          <year>2002</year>
          <volume>6</volume>
          <fpage>313</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">12585976</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bourgeois</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bastien</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Reynes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Makinson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rouanet</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lachaud</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>&#x2018;Active chronic visceral leishmaniasis&#x2019; in
HIV-1-infected patients demonstrated by biological and clinical long-term
follow-up of 10 patients</article-title>
          <source>HIV Med</source>
          <year>2010</year>
          <volume>11</volume>
          <fpage>670</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">20500233</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bourgeois</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lachaud</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Reynes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rouanet</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Mahamat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bastien</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Long-term monitoring of visceral leishmaniasis in
patients with AIDS: relapse risk factors, value of polymerase chain reaction, and
potential impact on secondary prophylaxis</article-title>
          <source>J Acquir Immune Defic Syndr</source>
          <year>2008</year>
          <volume>48</volume>
          <fpage>13</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">18300698</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Brasil</collab>
          </person-group>
          <article-title>Minist&#xE9;rio da Sa&#xFA;de. Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de.
Manual de recomenda&#xE7;&#xF5;es para diagn&#xF3;stico, tratamento e acompanhamento de pacientes
com a coinfec&#xE7;&#xE3;o <italic>Leishmania</italic>-HIV</article-title>
          <publisher-loc>Bras&#xED;lia</publisher-loc>
          <publisher-name>Minist&#xE9;rio da Sa&#xFA;de</publisher-name>
          <year>2011</year>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Brasil</collab>
          </person-group>
          <article-title>Minist&#xE9;rio da Sa&#xFA;de. Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de.
Aids no Brasil. Epidemia concentrada e estabilizada em popula&#xE7;&#xF5;es de maior
vulnerabilidade</article-title>
          <source>Bol Epidemiol AIDS/DST</source>
          <year>2011</year>
          <volume>8</volume>
          <issue>(1)</issue>
          <fpage>10</fpage>
          <lpage>5</lpage>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casado</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lopez-Velez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pintado</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Quereda</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Antela</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Relapsing visceral leishmaniasis in HIV-infected
patients undergoing successful protease inhibitor therapy</article-title>
          <source>Eur J Clin Microbiol Infect Dis</source>
          <year>2001</year>
          <volume>20</volume>
          <fpage>202</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">11347673</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavalcanti</surname>
              <given-names>ATA</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Andrade</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Magalh&#xE3;es</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnosing visceral leishmaniasis and HIV/AIDS
co-infection: a case series study in Pernambuco, Brazil</article-title>
          <source>Rev Inst Med Trop Sao Paulo</source>
          <year>2012</year>
          <volume>54</volume>
          <fpage>43</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">22370753</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cota</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Sousa</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Rabello</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Predictors of visceral leishmaniasis relapse in HIV
patients: a systematic review</article-title>
          <source>PLoS Negl Trop Dis</source>
          <year>2011</year>
          <volume>5</volume>
          <issue>(6)</issue>
          <fpage>e1153</fpage>
          <pub-id pub-id-type="pmid">21666786</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cruz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nieto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ca&#xF1;avate</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Desjeux</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alvar</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Leishmania/HIV co- infections in the second
decade</article-title>
          <source>Indian J Med Res</source>
          <year>2006</year>
          <volume>123</volume>
          <fpage>357</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="pmid">16778317</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daher</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Gerhard</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Leit&#xE3;o</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Silva J&#xFA;nior</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Clinical and epidemiological features of visceral
leishmaniasis and HIV co-infection in fifteen patients from Brazil</article-title>
          <source>J Parasitol</source>
          <year>2009</year>
          <volume>95</volume>
          <fpage>652</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">19642802</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fern&#xE1;ndez Cotarelo</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Abell&#xE1;n Mart&#xED;nez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Guerra Vales</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Mart&#xED;nez S&#xE1;nchez</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rodrigo G&#xF3;mez De La B&#xE1;rcena</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Salto Fern&#xE1;ndez</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Effect of highly active antiretroviral therapy on the
incidence and clinical manifestations of visceral leishmaniasis in human
immunodeficiency virus-infected patients</article-title>
          <source>Clin Infect Dis</source>
          <year>2003</year>
          <volume>37</volume>
          <fpage>973</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">13130410</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hailu</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Pre- and post-treatment antibody levels in visceral
leishmaniasis</article-title>
          <source>Trans R Soc Trop Med Hyg</source>
          <year>1990</year>
          <volume>84</volume>
          <fpage>673</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">2278067</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kubar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marty</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Leli&#xE8;vre</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Quaranta</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Staccini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Caroli-Bosc</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Visceral leishmaniosis in HIV-positive patients: primary
infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte
counts</article-title>
          <source>AIDS</source>
          <year>1998</year>
          <volume>12</volume>
          <fpage>2147</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">9833855</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lopez-Velez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Perez-Molina</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Guerrero</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baquero</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Villarrubia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Escribano</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinicoepidemiologic characteristics, prognostic
factors, and survival analysis of patients coinfected with human immunodeficiency
virus and <italic>Leishmania</italic> in an area of Madrid, Spain</article-title>
          <source>Am J Trop Med Hyg</source>
          <year>1998</year>
          <volume>58</volume>
          <fpage>436</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">9574788</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maia-Elkhoury</surname>
              <given-names>AN</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Sousa-Gomes</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Sena</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Luna</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
          <article-title>Visceral leishmaniasis in Brazil: trends and
challenges</article-title>
          <source>Cad Sa&#xFA;de P&#xFA;blica</source>
          <year>2008</year>
          <volume>24</volume>
          <fpage>2941</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">19082286</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marfurt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Niederwieser</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Makia</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Felger</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic genotyping of Old and New World Leishmania
species by PCR- RFLP</article-title>
          <source>Diagn Microbiol Infect Dis</source>
          <year>2003</year>
          <volume>46</volume>
          <fpage>115</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">12812715</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morales</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Rubio</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Chicharro</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ca&#xF1;avate</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Laguna</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Relapses versus reinfections in patients coinfected with
<italic>Leishmania infantum</italic> and human immunodeficiency virus type
1</article-title>
          <source>J Infect Dis</source>
          <year>2002</year>
          <volume>185</volume>
          <fpage>1533</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">11992294</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orsini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Luz</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Disch</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fernandes</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of <italic>Leishmania chagasi</italic>
from skin in <italic>Leishmania</italic>/HIV co-infection: a case
report</article-title>
          <source>Rev Soc Bras Med Trop</source>
          <year>2002</year>
          <volume>35</volume>
          <fpage>259</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">12045821</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pintado</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mart&#xED;n-Rabad&#xE1;n</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rivera</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bouza</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Visceral leishmaniasis in human immunodeficiency virus
(HIV)-infected and non-HIV infected patients</article-title>
          <source>Medicine (Baltimore)</source>
          <year>2001</year>
          <volume>80</volume>
          <fpage>54</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">11204503</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Prata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Domingues</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Leishmani&#xF3;ide d&#xE9;rmico</article-title>
          <source>O Hospital</source>
          <year>1955</year>
          <volume>50</volume>
          <fpage>93</fpage>
          <lpage>113</lpage>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenthal</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Marty</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>del Giudice</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pradier</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ceppi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gastaut</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HIV and <italic>Leishmania</italic> coinfection: a
review of 91 cases with focus on atypical locations of <italic>Leishmania</italic>
</article-title>
          <source>Clin Infect Dis</source>
          <year>2000</year>
          <volume>31</volume>
          <fpage>1093</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">11049794</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Russo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Laguna</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>L&#xF3;pez-V&#xE9;lez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Medrano</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Rosenthal</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cacopardo</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Visceral leishmaniasis in those infected with HIV:
clinical aspects and other opportunistic infections</article-title>
          <source>Ann Trop Med Parasitol</source>
          <year>2003</year>
          <volume>97</volume>
          <issue>(Suppl 1)</issue>
          <fpage>S99</fpage>
          <lpage>S105</lpage>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schonian</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nasereddin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dinse</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schweynoch</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schallig</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Presber</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PCR diagnosis and characterization of
<italic>Leishmania</italic> in local and imported clinical
samples</article-title>
          <source>Diagn Microbiol Infect Dis</source>
          <year>2003</year>
          <volume>47</volume>
          <fpage>349</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="pmid">12967749</pub-id>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <article-title>5<sup>th</sup> Consultative Meeting on Leishmania/HIV
Coinfection; 2007 Mar 20-22; Addis Ababa, ET</article-title>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <year>2007</year>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zijlstra</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Musa</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Khalil</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>el-Hassan</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>el-Hassan</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Post kala-azar dermal leishmaniasis</article-title>
          <source>Lancet Infect Dis</source>
          <year>2003</year>
          <volume>3</volume>
          <fpage>87</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">12560194</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
